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SUMMARY
The occurrence of metachronous adrenocortical carcinoma has rarely been described. We re-
port a case of a child with virilizing adrenocortical metachronous tumors that, despite several 
metastases, presented long-term survival (15 years). We analyzed in this tumor IGF2, IGF1R 
and FGFR4 gene expression, and evaluated the presence of p.R337H germline p53 mutation 
and somatic CTNNB1 mutation. IGF2 gene was over-expressed in both left (Weiss score 5) and 
right (Weiss 7) adrenocortical tumors. IGF1R expression levels were higher in the right adre-
nocortical tumor. FGFR4 over-expression was also detected in the right adrenocortical tumor. 
In addition, this patient harbors the germline p.R337H p53 mutation and loss of heterozygosity 
(LOH) was detected in the tumors. No somatic CTNNB1 mutations were found in both tumors. 
In conclusion, we demonstrated in this unusual case the over-expression of growth signaling 
pathways, which are molecular mechanisms previously related to adrenocortical tumorigene-
sis. Furthermore, the absence of somatic CTNNB1 mutations, which is a molecular marker of 
poor prognosis in adults, might be related to the long-term survival of this patient. Arq Bras Endo-
crinol Metab. 2011;55(1):72-7
SUMÁRIO
A ocorrência de carcinomas adrenocorticais metacrônicos é raramente relatada. Descrevemos 
o caso de uma criança portadora de tumor adrenocortical virilizante metacrônico que, apesar 
das inúmeras metástases, apresentou uma longa sobrevida (15 anos). Analisamos nesse tumor 
a expressão gênica de IGF2, IGF1R e FGFR4 e avaliamos a presença da mutação germinativa 
R337H no p53 e mutação somática no gene CTNNB1. O gene IGF2 foi hiperexpresso nos tumo-
res adrenocorticais esquerdo (Weiss 5) e direito (Weiss 7). Os níveis de expressão de IGF1R fo-
ram maiores no tumor direito. Hiperexpressão do gene FGFR4 também foi observada no tumor 
adrenocortical direito. Esse paciente é portador da mutação germinativa R337H no p53, e perda 
de heterozigose (LOH) foi observada em ambos os tumores. Não foram encontradas mutações 
no gene CTNNB1 nos tumores. Em conclusão, demonstramos neste caso a hiperexpressão de 
vias moleculares de crescimento, que são mecanismos previamente relacionados à tumorigê-
nese adrenocortical. Além disso, não encontramos mutações somáticas no gene CTNNB1, que 
é um marcador molecular de mau prognóstico em adultos e poderia estar relacionado à longa 
sobrevida desse paciente. Arq Bras Endocrinol Metab. 2011;55(1):72-7
IntROdUctIOn 
Adrenocortical carcinoma is a rare tumor in child-hood. However, the incidence of adrenocortical 
tumors in children under the age of 15 years (mostly 
diagnosed before the age of 4) in Southeast Brazil is ap-
proximately 10 times greater than the worldwide inci-
dence that ranges from only 0.3-0.38 million per year 
(1). A unique germline mutation of TP53 (R337H) 
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underlies the genetic predisposition in this population 
(1-3). Pediatric adrenocortical tumors appear to behave 
differently than histologically similar tumors in the adult 
population (4). Unlike the dismal survival statistics in 
adult adrenocortical carcinoma series, pediatric adreno-
cortical tumors with apparent poor prognosis on the ba-
sis of histopathological features may often have a better 
outcome (5). Unfortunately, there are no histological or 
molecular markers so far that can reliably distinguish be-
nign from malignant adrenocortical tumors and define 
the prognosis. Clearly, the extent of surgical resection is 
the most important factor in patient outcome (6). 
The mechanisms of adrenocortical tumorigenesis 
are still not fully understood, but several data suggest 
that malignant transformation is a multistep process (7). 
Molecular studies of sporadic adrenocortical tumors in 
the pediatric age group are limited due to the rarity of 
this condition, however, since children seem to have a 
better prognosis, it is important to determine whether 
the same molecular alterations described in adults are 
also present in children, and whether this is related to 
the outcome. We report the case of adrenocortical me-
tachronous tumors presenting in a child with long-term 
survival, emphasizing different molecular pathways that 
could be involved in the adrenocortical tumorigenesis 
and related to the benign evolution of this patient. 
cASe RepORt
This study was approved by the Ethics Committee of 
Hospital das Clínicas (São Paulo, Brazil). The parents 
of this child provided informed consent, including for 
the use of the photographs, images and the report that 
follows. The patient was born full term after an uncom-
plicated pregnancy and delivery. At 2 years and 2 mon-
ths of age, the child presented with signs of virilization 
(pubic hair, penis enlargement, growth acceleration and 
aggressiveness) (Figure 1). At that time, his weight and 
height were 18.0 kg and 100.0 cm respectively (hei-
ght SD + 3.74). At physical examination he was found 
to have virilization described as prepubertal testis and 
more recent facial acne, deepening of the voice, and in-
creased muscle mass, but no abdominal mass was palpa-
ble. The family history was unremarkable. Laboratory 
evaluation demonstrated undetectable gonadotropins 
and abnormally elevated adrenal steroid levels: DHEA-
-S, 1790 ng/mL [normal range < 194 ng/mL]; an-
drostenedione, 2.0 ng/mL [normal range < 0.3-2.9 
ng/mL], and testosterone, 395 ng/dL [normal ran-
ge < 19 ng/dL], characterizing isosexual precocious 
puberty independent of gonadotropins. Abdominal 
computerized tomography (CT) showed a 2.0 cm mass 
in the left adrenal gland (Figure 2). The patient un-
derwent surgical procedure and an adrenal mass with 
3.0 g of weight and 2.5 cm of diameter was resected.
The adrenocortical tumor had a histological Weiss 
score of 5 (8) and the MacFarlane modified by Sullivan 
staging was I (9) (Table 1). Postoperatively, the signs of 
virilization disappeared and all tumor markers returned 
to their normal ranges. At that time, the patient recei-
ved no further treatment. 
Two years after surgery the patient presented signs 
of virilization all over again and, in addition, frequent 
erections. Hormonal studies revealed elevated androgen 
levels (DHEA-S, 6,905 ng/mL [normal range, < 194 
ng/mL]; androstenedione, 8.1 ng/mL [normal range, 
0.3-2.9 ng/mL], and testosterone, 403 ng/dL [normal 
range < 19 ng/dL]). A novel right adrenal mass was dis-
covered by an abdominal CT (Figure 3). No secondary 
lesions were detected by radiological studies at this time. 
The patient underwent surgical resection and intraopera-
tive findings revealed a large (8.5 cm) tumor in the right 
adrenal gland. The mass was apparently adherent to the 
kidney and a freezing biopsy showed invasion of the cap-
sule of the liver. The tumor was removed together with 
the right kidney and with a small portion of the right 
lobe of the liver. The weight of the tumor was 30.0 g and 
histological analysis revealed a Weiss score 7. Although 
no signs of invasion of the liver itself or the kidney were 
observed the tumor was classified as a carcinoma (Ma-
cFarlane modified by Sullivan staging III) (Table 1). 
Due to the poor prognosis associated with this diagno-
sis by the observation of invasion of the liver capsule by 
freezing biopsy, the patient was immediately started on 
mitotane. The dose was gradually increased to 1 g/d. 
The patient was also treated with replacement doses of 
cortisone acetate and fludrocortisone. Five months af-
ter tumor resection, the patient developed gynecomastia 
and severe neurologic side effects, and mitotane was dis-
continued. He continued to receive steroid replacement, 
and his adrenal markers remained undetectable.
At 7 years and 8 months of age, his DHEA-S levels 
increased to 272 ng/mL. This relapse was secondary to 
a pulmonary metastasis, which was treated by surgery. 
Histology confirmed metastatic nodule of adrenocorti-
cal carcinoma. Seven months after this surgery, a novel 
elevation of DHEA-S levels was observed. A Positron 
emission tomography-fludeoxyglucose (PET-FDG) scan 
and a chest CT showed a left hilar pulmonary metastasis, 
which was successfully removed by surgical procedure.
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Figure 1. Independent gonadotropins precocious puberty. Enlargement of 
the penis with prepubertal testis.
Figure 2. Abdominal computerized tomography showing a 2.0 cm mass in 
the left adrenal gland. 
table 1. Microscopic pathological assessment according to Weiss system 
First adrenal tumor
Left adrenal tumor with 2.5 cm of 
diameter and 3.0 g of weight
Second adrenal tumor
Right adrenal tumor with 8.5 cm of 
diameter and 30.0 g of weight (tumor 
+ right kidney = 175.0 g)
Cytological alterations
1) Nuclear grade 4 according to 
Fuhrman’s criteria 
1) Nuclear grade 4 according to 
Fuhrman’s criteria
2) Mitotic rate 13 per 50 high-power 
fields
2) Mitotic rate 51 per 50 high-power 
fields 
3) Atypical mitosis 3) Atypical mitosis
Structural alterations
4) Clear cells comprising 25% or less 
of the tumor (predominance of 
eosinophilic cells)
4) Clear cells comprising 25% or less 
of the tumor (predominance of 
eosinophilic cells)
5) Diffuse architecture > 1/3 of tumor 5) Diffuse architecture > 1/3 of the 
tumor
6) Necrosis involving a confluent area 
of cells
Invasion type 
7) Invasion of capsule of tumor*
Weiss score 5 Weiss score 7
* : There was tumor capsule invasion but hepatic tissue biopsy was normal.
In childhood adrenocortical tumors the criteria of Weiss classically used in the adult population 
have no correlation with biological behavior. In this context the first tumor was diagnosed as a 
tumor of the adrenal cortex with questionable prognosis. In contrast, the second tumor was 
clearly an adrenocortical carcinoma.
Figure 3. Abdominal computerized tomography showing a 8.0 cm mass in 
the right adrenal gland.
Nowadays, the patient is 17 years old with no evi-
dence of new metastasis based on radiological imaging 
follow-up.
MethOdS And ReSUltS
Molecular analysis
We have studied different molecular pathways rela-
ted to the pathophysiology in a male pediatric case of 
metastatic adrenocortical carcinoma with long-term 
follow-up and insidious evolution. In trying to clari-
fy the atypical tumor behavior in this case we investi-
gated the expression of different genes in the tumor’s 
tissue: insulin growth factor 2 (IGF2, Taqman assay 
Hs01005963_m1, Applied Biosystems, Foster City, CA, 
USA) and its receptor (IGF1R, assay Hs00181385_m1) 
and fibroblast growth factor receptor 4 (FGFR4, assay 
Hs00242558_m1). Quantitative real-time PCR was 
performed as previously described (10,11). IGF2 gene 
was over-expressed in both left (Weiss score 5) and ri-
ght (Weiss 7) adrenocortical tumors. IGF1R expression 
levels were higher in the right adrenocortical tumor 
(fold change, 7.4 vs. 3.32).
We also analyzed the presence of mutations in a 
particular region of genes coding for p53, a tumor su-
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ppressor, and for beta-catenin (CTNNB1), a key com-
ponent of Wnt pathway.
Tumor DNA was extracted according to standard 
procedures. Mutational analysis involving exon 3 of the 
CTNNB1 gene, which encodes beta-catenin, was per-
formed using flaking intronic sequences of this exon. 
The primers used were 5’ TGGGTCATATCACA-
GATTCTTTTTTT 3’ and 3’TCAAAACTGCATTCT-
GACTTTCA 5’. PCR was performed employing TAQ 
DNA polymerase (Promega). The amplified product 
was submitted to direct sequencing on an automated 
sequencer (ABI 7000 sequencer detection system − 
Applied Biosystems). Mutations were verified in both 
sense and anti-sense directions. The entire exon 10 of 
the TP53 gene was amplified and sequenced. In addi-
tion loss of heterozygosity (LOH) was studied in both 
tumors as previously described (1,2). The patient was 
found to be a carrier of the TP53 R337H germinal mu-
tation in a heterozygosis pattern, which seems to be as-
sociated with a predisposition to adrenocortical tumors 
without prognostic implications (2). In addition, LOH 
was detected in the left and right tumors. Analysis of 
CTNNB1 exon 3 showed no alterations in both left 
and right tumors in comparison to wild type gene. 
Immunohistochemical analysis
To investigate the role of Wnt/beta-catenin signaling 
in tumorigenesis, beta-catenin expression was studied 
by immunohistochemistry using a monoclonal mou-
se anti-human beta-catenin antibody at the dilution 
of 1:200 (code: M3539 − Dakocytomation). In addi-
tion, we performed immunohistochemistry of p53, by 
P53 antibody at the dilution of 1:1000 (Clone DO7 
− Dakocytomation).
The usual distribution of beta-catenin at the plasma 
membrane was demonstrated with no nucleus/cytoplas-
mic staining, which is the normal pattern, since beta-
-catenin plays a role in the cell-cell adhesion with cadhe-
rin (12). P53 immunohistochemistry analyzes showed 
abnormal nuclear staining as expected, as the patient is 
a carrier of R337H mutation in TP53 (1,13) (Figure 4).
dIScUSSIOn
The diagnosis of adrenocortical tumors in children is 
suspected mainly based on clinical signs and symptoms 
of androgen hormones in excess, causing precocious 
pubarche. The occurrence of isolated Cushing’s Syn-
Figure 4. Immunohistochemical staining of p53. Nuclear 
immunoexpression for p53 in the right adrenocortical tumor. 400 x.
drome due to the production of glucocorticoid by an 
adrenocortical tumor is infrequent (3). Routine evalu-
ation for suspected adrenocortical tumors consists in 
the measurement of: DHEA-S, testosterone, estradiol, 
LH, FSH, ACTH, androstenedione, 17-hydroxypro-
gesterone, aldosterone, renin activity, 11-deoxycorti-
sol, and cortisol after low dose of overnight dexame-
thasone (5). To date, adrenocortical tumors in children 
are unequivocally established as carcinomas due to local 
recurrence or metastasis development. However, dis-
tinction between adenoma and carcinoma can be very 
difficult to accomplish when adrenocortical neoplasms 
are diagnosed in the early stages, since there is yet no 
reliable marker to predict tumor recurrence or dissemi-
nation. Pediatric adrenocortical tumors classified as car-
cinomas based solely on histopathological Weiss criteria 
often have favorable prognosis (14). Wieneke and cols. 
(4) described some factors that when identified in the 
aggregate appear to accurately predict a more aggres-
sive biologic behavior, which includes: tumor weight > 
400 g, tumor size > 10.5 cm, extension into periadrenal 
soft tissues and/or adjacent organs, invasion into the 
vena cava, venous invasion, capsular invasion, presen-
ce of tumor necrosis, > 15 mitoses per 20 HPF, and 
presence of atypical mitosis figures (4). Of note is the 
presence of some of these histopathological criteria in 
both tumors presented by the child (Table 1), however, 
the tumors’ weights and sizes are beneath these ranges. 
Among various clinical parameters that have been sho-
wn to impact adrenocortical carcinoma prognosis, tu-
mor staging has been demonstrated as one of the most 
important (13). The staging system for adrenocortical 
carcinomas depends upon tumor size, nodal involve-
Pediatric metachronous adrenocortical tumor
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ment, invasion of adjacent organs, and presence of dis-
tant metastasis (9). However, it is important to know 
that is not uncommon for patients with small tumors to 
experience relapses.
The pathophysiological study of the adrenocortical 
carcinoma is important to improve diagnosis, prognos-
tic evaluation, and treatment. Analysis of exon 10 of 
the TP53 gene revealed that our patient is a carrier of 
TP53 R337H germinal mutation as is the majority of 
pediatric Brazilian patients with adrenocortical tumors. 
This mutation is not related to a dismal behavior of 
this disease (2). IGF2 overexpression has been consis-
tently demonstrated in adult sporadic adrenocortical 
carcinomas. IGF2 exerts its mitogenic effects through 
interaction with IGF1R (15). Almeida and cols. (10) 
reported overexpression of IGF2 in both pediatric 
adrenocortical adenomas and carcinomas; on the other 
hand, IGF1R m RNA levels were significantly higher 
in childhood adrenocortical carcinomas. Both adreno-
cortical tumors reported here had a high expression of 
IGF2 and IGF1R, but IGF1R expression was higher in 
the right tumor. Studies have demonstrated that an-
tagonizing the IGF signaling pathway with pharmaco-
logical agents results in the inhibition of in vitro and 
in vivo tumor cell growth. This raises the prospect of 
using target disruption of the IGF1R signaling pathway 
as a therapeutic agent since this targeted inhibition was 
apparently more potent than the use of mitotane in xe-
nograft growth (10,15). 
Tissier and cols. (16) reported beta-catenin ano-
malous staining at the nucleus and/or cytoplasm in a 
high frequency of adult adrenocortical tumors, mainly 
in carcinomas. However, the pattern differed between 
these tumors. The abnormal beta-catenin immunostai-
ning was focal in most adrenocortical adenomas and 
diffuse in adrenocortical carcinomas. Until now, the-
re is little information in medical literature about the 
participation of the Wnt pathway in pediatric adreno-
cortical tumorigenesis. Pusantisampan T and cols. (17) 
reported a case of a child with metastatic adrenocorti-
cal carcinoma presenting a somatic mutation of beta-
-catenin. Recently, somatic activating mutations of the 
CTNNB1 gene were associated as a poor prognostic 
factor in adult adrenocortical carcinomas (18). In the 
present case, neither abnormal beta-catenin staining, 
nor mutation in the exon 3 beta catenin gene was ob-
served. The absence of this somatic molecular altera-
tion might be related to the indolent behavior of the 
patient’s tumors.
A previous microarray analysis of pediatric adre-
nocortical tumors demonstrated high of expression of 
FGFR4 (19). In fact, an overexpression of FGFR4 was 
observed in the tumors of the patient reported. 
Surgical resection is the treatment of choice for pa-
tients with resectable primary and even metastatic le-
sions (6). In addition, adjuvant mitotane therapy may 
be given to patients in MacFarlane stage III and IV to 
increase the length of time between recurrences. Mito-
tane has a cytotoxic effect on adrenocortical cells and it 
is effective in controlling steroid excess in patients with 
secreting adrenocortical carcinoma; but patients often 
present symptoms due to the toxicity of this drug, whi-
ch is largely related to mitotane blood levels. Mitotane 
has been extensively used in adults, but there is little 
knowledge of its efficacy and long-term effects in chil-
dren. The role of chemotherapy in the management of 
adrenocortical carcinoma in children is not clear. 
After surgical procedures the patient presented 
good evolution and to date he is receiving glycocor-
ticoid and mineralocorticoid replacement. Puberty has 
developed at the expected age and the patient achieved 
the target high. It is important to emphasize that the 
cure achieved for this particular patient may be related 
to total resection of the tumors and also of the metas-
tasis. Of note, there is a risk for recurrence even after 
10-12 years and complete resection of both adrenocor-
tical tumors and metastasis. Continued surveillance is 
still required. Also, we do not recommend this patient, 
being a carrier of the TP53 mutation, to smoke or have 
contact with substances that might damage his DNA.
Disclosure: no potential conflict of interest relevant to this article 
was reported. 
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